Discovery of novel mutations in the dihydropyrimidine dehydrogenase gene associated with toxicity of fluoropyrimidines and viewpoint on preemptive pharmacogenetic screening in patients

EPMA Journal

Volumn 6, Issue 1, 2015, Pages

  Del Re, Marzia ^a   Michelucci, Angela ^b   Di Leo, Angelo ^c   Cantore, Maurizio ^d   Bordonaro, Roberto ^e   Simi, Paolo ^b   Danesi, Romano ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

^c Oncology Unit   (Italy)

^d CARLO POMA HOSPITAL   (Italy)

^e Azienda Ospedaliera Garibaldi   (Italy)

Author keywords

Colorectal cancer; DPD; Fluoropyrimidines; Prediction, Personalization, Medicine; Toxicity

Indexed keywords

ADENINE; BEVACIZUMAB; CAPECITABINE; CYTOSINE; DIHYDROPYRIMIDINE DEHYDROGENASE; DNA; FLUOROURACIL; FOLINIC ACID; GUANINE; IRINOTECAN; OXALIPLATIN;

ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ARTICLE; CANCER PROGNOSIS; CANCER SURGERY; CASE REPORT; COLON CARCINOMA; COLORECTAL CARCINOMA; CONTINUOUS INFUSION; DIARRHEA; DNA EXTRACTION; DPYD GENE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EXON; FEMALE; FEVER; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; MIDDLE AGED; MUTATIONAL ANALYSIS; NAUSEA AND VOMITING; NEUTROPENIA; PATIENT CARE; PHENOTYPE; PRIORITY JOURNAL; SIGMOID CARCINOMA; STOMATITIS;

EID: 84940503513     PISSN: 18785077     EISSN: 18785085     Source Type: Journal    
DOI: 10.1186/s13167-015-0039-x     Document Type: Article

References (28)

1. Walko CM, Lindley C. Capecitabine: a review. Clin Ther. 2005;27:23-44.
2. Tanaka F, Fukuse T, Wada H, Fukushima M. The history, mechanism and clinical use of oral 5-fluorouracil derivative chemotherapeutic agents. Curr Pharm Biotechnol. 2000;1:137-64.
3. Johnson MR, Hageboutros A, Wang K, High L, Smith JB, Diasio RB. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res. 1999;5:2006-11.
4. Amstutz U, Froehlich TK, Largiadèr CR. Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. Pharmacogenomics. 2011;12:1321-36.
5. Keller G, Hartmann A, Mueller J, Höfler H. Denaturing high pressure liquid chromatography (DHPLC) for the analysis of somatic p53 mutations. Lab Invest. 2001;81:1735-7.
6. Saif MW, Ezzeldin H, Vance K, Sellers S, Diasio RB. DPYD*2A mutation: the most common mutation associated with DPD deficiency. Cancer Chemother Pharmacol. 2007;60:503-7.
7. van Kuilenburg AB, De Abreu RA, van Gennip AH. Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency. Ann Clin Biochem. 2003;40:41-5.
8. Kleibl Z, Fidlerova J, Kleiblova P, Kormunda S, Bilek M, Bouskova K, et al. Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy. Neoplasma. 2009;56:303-16.
9. Johnson MR, Wang K, Diasio RB. Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. Clin Cancer Res. 2002;8:768-74.
10. Collie-Duguid ESR, Etienne MC, Milano G, McLeod HL. Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics. 2000;10:217-23.
11. He YF, Wei W, Zhang X, Li YH, Li S, Wang FH, et al. Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in Chinese cancer patients. J Clin Pharm Ther. 2008;33:307-14.
12. Newbold RJ, Deery EC, Walker CE, Wilkie SE, Srinivasan N, Hunt DM, et al. The destabilization of human GCAP1 by a proline to leucine mutation might cause cone-rod dystrophy. Hum Mol Genet. 2001;10:47-54.
13. Yen JL, McLeod HL. Should DPD analysis be required prior to prescribing fluoropyrimidines? Eur J Cancer. 2007;43:1011-6.
14. Terrazzino S, Cargnin S, Del Re M, Danesi R, Canonico PL, Genazzani AA. DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis. Pharmacogenomics. 2013;14:1255-72.
15. Innocenti F. DPYD variants to predict 5-FU toxicity: the ultimate proof. J Natl Cancer Inst. 2014;106. doi: 10.1093/jnci/dju351 .
16. Goldstein DA, Shaib WL, Flowers CR. Costs and effectiveness of genomic testing in the management of colorectal cancer. Oncology (Williston Park). 2015;29(3):175-83.
17. Golubnitschaja O, Costigliola V, EPMA. General report & recommendations in predictive, preventive and personalised medicine 2012: white paper of the European Association for Predictive, Preventive and Personalised Medicine. EPMA J. 2012;3:1-53.
18. Zhang H, Li YM, Zhang H, Jin X. DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: results from genotyping study on 75 gastric carcinoma and colon carcinoma patients. Med Oncol. 2007;24:251-8.
19. van Kuilenburg AB, Haasjes J, Meinsma R, Waterham HR, Vreken P, van Gennip AH. Dihydropyrimidine dehydrogenase (DPD) deficiency: novel mutations in the DPD gene. Adv Exp Med Biol. 2000;486:247-50.
20. Morel A, Boisdron-Celle M, Fey L, Lainé-Cessac P, Gamelin E. Identification of a novel mutation in the dihydropyrimidine dehydrogenase gene in a patient with a lethal outcome following 5-fluorouracil administration and the determination of its frequency in a population of 500 patients with colorectal carcinoma. Clin Biochem. 2007;40:11-7.
21. Gross E, Busse B, Riemenschneider M, Neubauer S, Seck K, Klein HG, et al. Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients. PLoS One. 2008;3:e4003.
22. Shahrokni A, Rajebi MR, Harold L, Saif MW. Cardiotoxicity of 5-fluorouracil and capecitabine in a pancreatic cancer patient with a novel mutation in the dihydropyrimidine dehydrogenase gene. JOP. 2009;10:215-20.
23. Vreken P, van Kuilenburg ABP, Meinsma R, De Abreu RA, VanGennip AH. Dihydropyrimidine dehydrogenase (DPD) deficiency: identification and expression of missense mutations C29R, R886H and R235W. Hum Genet. 1997;101:333-8.
24. Morel A, Boisdron-Celle M, Fey L, Soulie P, Craipeau MC, Traore S, et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5 fluorouracil tolerance. Mol Cancer Ther. 2006;5:2895-904.
25. Gross E, Ullrich T, Seck K, Mueller V, de Wit M, von Schilling C, et al. Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5 fluorouracil related side effects. Hum Mutat. 2003;22:498-506.
26. van Kuilenburg AB, Haasjes J, Richel DJ, Zoetekouw L, Van Lenthe H, De Abreu RA, et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res. 2000;6:4705-12.
27. Mercier C, Ciccolini J. Severe or lethal toxicities upon capecitabine intake: is DPYD genetic polymorphism the ideal culprit? Trends Pharmacol Sci. 2007;28:597-8.
28. Ben Fredj R, Gross E, Chouchen L, B'Chir F, Ben Ahmed S, Neubauer S, et al. Mutational spectrum of dihydropyrimidine dehydrogenase gene (DPYD) in the Tunisian population. C R Biol. 2007;330:764-9.